A lady from Florida whose father died from a stroke after four days he started to take Xarelto filed a Xarelto lawsuit in Philadelphia claiming that the drug was not marketed fairly and didn’t work as advertised. It is the first lawsuit claiming that Xarelto failed to prevent strokes in a patient with abnormal heartbeat condition. The xarelto lawsuit against Bayer and Johnson & Johnson are merged in two courts, a multidistrict litigation court in the Eastern District of Louisiana and a mass tort court in Philadelphia. Thousands of people have filed lawsuit against manufacturer bayer and Johnson & Johnson so far claiming that blood thinner Xarelto caused them to suffer xarelto side effects like uncontrollable bleeding. A remark was made by advisory committee in 2011 that “If rivaroxaban is approved, the person taking it might be at risk of harm from stroke or bleeding”.
If a defendant loses multiple trials, the jury tries to settle large numbers of cases to avoid additional negative verdicts. Also, if the claimant knows that the case they are filing is weak, they can settle bellwether cases prior to trials. The first bellwether trial date has been set to Feb’17 and following that there will be additional trials which are scheduled in March, April and May. Bellwether trial are the first Xarelo case to be presented before a jury. They often consolidate the similar claims so plaintiffs can determine how future trials will be addressed. .
A study in 2014 found the amount of Xarelto in a patient’s body fluctuated more than three times as in if compared to an anticoagulant, Eliquis (apixaban), taken twice daily The FDA approved Xarelto to lessen the risk of stroke in patients with atrial fibrillation in 2011, but one FDA reviewer recommendation was against the drug’s approval “The data do not convincingly demonstrate that rivaroxaban (Xarelto) is as effective in preventing strokes and systemic emboli (blood clots) as warfarin when warfarin is used skillfully,” the reviewer wrote to the advisory committee in 2011. “If rivaroxaban is approved, patients taking it might be at greater risk of harm from stroke and/or bleeding.”